Officer sold ~$215K of Cytokinetics
Automatic saleLoading…
CYTK · NASDAQ · Biotechnology
Biotechnology company based in South San Francisco, California.
In the last 90 days, no insider of Cytokinetics reported an open-market purchase and 18 open-market sales worth about $13.7M. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 5, 2026
$62.70
Last 12 months
Not enough history
Market value
$8.72B
Revenue
$28.6M
−57.1% vs the same quarter a year earlier
Free cash flow, last 12 months
−$581M
This quarter −$164M, a year earlier −$132M
Net debt
$20.3M
Debt $276M, cash $255M, at Jun 30, 2026
Net income, last 12 months
−$894M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
18 sales
$13.7M sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2025
$88M
+376.6% vs the year before
Net income, fiscal 2025
−$785M
A loss for the year
Shares outstanding
139M
As of Aug 4, 2026
Officer sold ~$215K of Cytokinetics
Automatic saleCEO sold ~$491K of Cytokinetics
Automatic saleOfficer sold ~$239K of Cytokinetics
Automatic saleCEO sold ~$551K of Cytokinetics
Scheduled in advancePrices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Last 12 months, adjusted daily closes
Adjusted close went from $60.64 on Oct 6, 2025 to $62.70 on Oct 5, 2026 (+3.4%). Disclosed activity in the last 12 months: 0 insider purchases, 88 insider sales (88 under pre-arranged plans), 0 Congress purchases, 0 Congress sales.
4 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in symptomatic non-obstructive hypertrophic cardiomyopathy, symptomatic heart failure with preserved ejection fraction (hfpef), heart failure. The ones with the nearest registered primary completion date still ahead:
2 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.